Doxorubicin-induced cardiomyopathy 17 years after chemotherapy

Texas Heart Institute Journal

Volumn 39, Issue 3, 2012, Pages 424-427

  Kumar, Simi ^a   Marfatia, Ravi ^a   Tannenbaum, Susan ^a   Yang, Clifford ^a   Avelar, Erick ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Adult; Cardiomyopathies chemically induced; Cardiovascular diseases therapy; Doxorubicin adverse effects; Heart failure chemically induced; Left drug effects; Risk factors; Ventricular function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIGOXIN; DOXORUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; METOPROLOL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; CASE REPORT; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; DYSPNEA; FEMALE; HEART ATRIUM ENLARGEMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOKINESIA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOW DRUG DOSE; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; QRS COMPLEX; SINUS TACHYCARDIA; TACHYPNEA;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY, SEGMENTAL; MIDDLE AGED; RECOVERY OF FUNCTION; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84864107434     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94(4):525-33.
2. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53(24):2231-47.
3. Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, Priebat DA, et al. Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging. Clin Nucl Med 2009;34(11): 762-7.
4. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology 2010;115(2):155-62.
5. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52(4):274-88.
6. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50(15):1435-41.
7. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis 2010;53(2):94-104.
8. Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 2005;25(9):1271-6.
9. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11):2869-79.
10. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107(9):1375-80.
11. Gottlieb SL, Edmiston WA Jr, Haywood LJ. Late, late doxorubicin cardiotoxicity. Chest 1980;78(6):880-2.
12. Lishner M, Elis A, Ravid M. Late doxorubicin cardiotoxicity. Anticancer Drugs 1992;3(4):367-9.
13. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med 1986;80(3): 483-5.
14. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125(1):47-58.